GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Maridebart Cafraglutide

Company
Amgen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
8 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

8 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Maridebart Cafraglutide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07037433

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    Not yet reported Amgen 12800 participants Est. completion 2030-09-29 783 sites Stand-alone
    Cardiovascular disease Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07037459

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Not yet reported Amgen 5056 participants Est. completion 2030-09-29 628 sites Stand-alone
    Heart failure Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07225686

    Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

    Not yet reported Amgen 250 participants Est. completion 2028-09-13 61 sites Stand-alone
    Obstructive sleep apnea Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07226765

    Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

    Not yet reported Amgen 250 participants Est. completion 2028-09-13 57 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Recruiting NCT NCT07441252

    A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

    Not yet reported Amgen 180 participants Est. completion 2027-12-22 23 sites Stand-alone
    Other conditions: Overweight or Obesity and Elevated Liver Fat
    View official trial listing →
  • Recruiting NCT NCT07575399

    Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

    Not yet reported Amgen 300 participants Est. completion 2028-02-28 45 sites Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
  • Recruiting NCT NCT07684144

    Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    Not yet reported Amgen 950 participants Est. completion 2028-03-19 37 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07684235

    Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    Not yet reported Amgen 3200 participants Est. completion 2028-03-19 87 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT04478708

    Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

    Not yet reported Amgen 110 participants Est. completion 2022-11-18 3 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT05056246

    Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

    Not yet reported Amgen 34 participants Est. completion 2022-04-08 1 site
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT05669599

    Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

    Not yet reported Amgen 592 participants Est. completion 2025-12-16 78 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06352892

    A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight

    Not yet reported Amgen 20 participants Est. completion 2024-08-27 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06660173

    A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Amgen 409 participants Est. completion 2026-11-10 96 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06858839

    Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

    Not yet reported Amgen 3853 participants Est. completion 2027-04-16 243 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06858878

    Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

    Not yet reported Amgen 1105 participants Est. completion 2027-04-16 187 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06976372

    A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

    Not yet reported Amgen 120 participants Est. completion 2024-12-27 3 sites
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06987695

    Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

    Not yet reported Amgen 279 participants Est. completion 2027-07-21 30 sites Stand-alone
    Other conditions: Obesity Disease
    View official trial listing →
  • Active, not recruiting NCT NCT07160257

    A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

    Not yet reported Amgen 56 participants Est. completion 2027-03-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07226778

    Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

    Not yet reported Amgen 348 participants Est. completion 2026-05-28 4 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07229157

    Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

    Not yet reported Amgen 81 participants Est. completion 2026-08-26 2 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT07313761

    A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

    Not yet reported Amgen 349 participants Est. completion 2026-07-02 4 sites Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT07429032

    The Effect of AMG 133 on Gastric Emptying

    Not yet reported Amgen 57 participants Est. completion 2025-11-26 1 site
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT07429045

    A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

    Not yet reported Amgen 44 participants Est. completion 2025-11-21 5 sites
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07523711

    Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

    Not yet reported Amgen 49 participants Est. completion 2026-11-18 2 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT07717814

    A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity

    Not yet reported Amgen 154 participants Est. completion 2025-06-02 4 sites
    Other conditions: Overweight and Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.